This tool was designed to help you assess the grade of the adverse event reported by your patient and to get dosing modifications recommendations based on the grade of the event as per the approved LORBRENA Prescribing Information.
 
  • Step 1: select an adverse event (see most common adverse reactions below, please use our search functionality or switch to view the full list)
  • Step 2: assess the grade of the adverse event as per CTCAE 4.03 criteria
  • Step 3: determine appropriate dosing modifications strategies

If you need additional information (including the incidence of the adverse events occurring in the pivotal lorlatinib randomized clinical trials), please consult the approved LORBRENA® Prescribing Information, search through our collection of scientific response documents or contact us directly ( submit a request online, or call (800) 438-1985).
 
Pfizer is unable to make any specific dosage and/or treatment recommendations for individual patients beyond lorlatinib dosage modifications as described in the LORBRENA Prescribing Information; clinical judgment based on the medical history and the clinical status of a specific patient will dictate the appropriate actions to be taken.
 
Dosing interruption and/or dose reductions for LORBRENA are recommended based on individual safety and tolerability. Please refer to the full LORBRENA Prescribing Information for dosing recommendations and dose adjustment guidelines in the event of toxicity.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.